Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Implications for Risk Prediction
Antonis C. Antoniou(Weatherford College), Maya Dubrovsky(Sheba Medical Center), Fergus J. Couch(Mayo Clinic), Kathleen Claes(Statistics Belgium), Noralane M. Lindor(Mayo Clinic in Arizona), Jeffrey N. Weitzel(Cancer Genetics (United States)), Eitan Friedman(University of Pennsylvania), Flavio Lejbkowicz(Carmel Medical Center), Siranoush Manoukian(Fondazione IRCCS Istituto Nazionale dei Tumori), Lenka Foretová(Masaryk Memorial Cancer Institute), Valentina Dall’Olio(IFOM), Bella Kaufman(NYU Langone Health), Irene L. Andrulis(University of Toronto), Yuan Chun Ding(University of Copenhagen), Gail E. Tomlinson(Urology San Antonio), Olufunmilayo I. Olopade(University of Chicago), Csilla I. Szabo(University of Delaware), Bruce Poppe(Ghent University Hospital), Gord Glendon(University Health Network), Daniela Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Susan L. Neuhausen(City of Hope), Yael Laitman(City Of Hope National Medical Center), Claudine Isaacs(Georgetown University), Michal Zikán(Charles University), Lone Sunde(Aalborg University Hospital), Anne‐Marie Gerdes(Copenhagen University Hospital), Roni Milgrom(Sheba Medical Center), Gad Rennert(Technion – Israel Institute of Technology), Bernard Peissel(Sapienza University of Rome), Xianshu Wang(Kunming University of Science and Technology), Uffe Birk Jensen(Aarhus University Hospital), V. Shane Pankratz(University of New Mexico), Mark H. Greene(Cancer Institute (WIA)), Mads Thomassen(City Of Hope National Medical Center), Jonathan Beesley(The University of Melbourne), Patricia A. Ganz(Los Angeles County Department of Public Health), Paolo Peterlongo(IFOM), Paolo Radice(IFOM), Monica Barile(European Institute of Oncology), Hilmi Özçelik(Mount Sinai Hospital), Lesley McGuffog(University of Cambridge), Sue Healey(QIMR Berghofer Medical Research Institute), Timothy R. Rebbeck(University of Pennsylvania), Henry T. Lynch(Creighton University), Dorthe Gylling Crüger(Vejle Sygehus), Olga M. Sinilnikova(Hospices Civils de Lyon), Maria A. Caligo(Azienda Ospedaliera Universitaria Pisana), Alessandra Viel(Centro di Riferimento Oncologico), Anna Allavena(University of Turin)
Cited by 184
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Analysis of shared heritability in common disorders of the brain
|Science|2018|2k